This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-17 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
== Selected awards and honors == 1977 E. Mead Johnson Award for Pediatric Research, New York, NY. 1987 Distinguished Alumnus Award, New Jersey College of Medicine, Newark, NJ. 1994 Selected as one of "The POZ 50," individuals who have most influenced the course of HIV/AIDS. 1995 AmFAR's Outstanding Research in Pediatric AIDS Award. Presented on World's AIDS Day. 2000 American Society of Microbiology Heroes in Medicine Award 2001 Research in Action Award. Presented by Treatment Action Group. December 8, 2001. New York, NY. 2007 Wheaton College Outstanding Alumnus Award for Service to Humanity 2010/2011 Purpose Prize Fellow Encore Career for continued dedication to issues of justice and equity. 2013 Bakken Invitation Honoree.
=== Storage and disposal === The fentanyl patch is one of a few medications that may be especially harmful, and in some cases fatal, with just one dose, if misused by a child. In British Columbia, Canada, where there are environmental concerns about toilet flushing or garbage disposal, pharmacists recommend that unused patches be sealed in a child-proof container that is then returned to a pharmacy. In the United States, where patches cannot always be returned through a medication take-back program, flushing is recommended for fentanyl patches, because it is the fastest and surest way to remove them from the home, preventing ingestion by children, pets or others not intended to use them.
In in vitro kinetic experiments measuring OGT and OGA activity on a panel of protein substrates, kinetic parameters for OGT were shown to be variable between various proteins while kinetic parameters for OGA were relatively constant between various proteins. This result suggested that OGT is the "senior partner" in regulating O-GlcNAc and OGA primarily recognizes substrates via the presence of O-GlcNAc rather than the identity of the modified protein.
=== Brand names === Oxazepam is marketed under many brand names worldwide, including: Alepam, Alepan, Anoxa, Anxiolit, Comedormir, durazepam, Medopam, Murelax, Nozepam, Noripam, Oksazepam, Opamox, Ox-Pam, Oxa-CT, Oxabenz, Oxamin, Oxapam, Oxapax, Oxascand, Oxaze, Oxazepam, Oxazépam, Oxazin, Oxepam, Praxiten, Purata, Selars, Serax, Serepax, Seresta, Séresta, Serenid, Serpax, Sobril, Delipam, Tazepam, Vaben, and Youfei. It is also marketed in combination with hyoscine as Novalona and in combination with alanine as Pausafrent T.
Sources: en.wikipedia.org
Evidence of a consistent pattern of basalt acquisition by the Middle Pleistocene hominins for the production of Acheulian tools from the Gesher Benot Ya'aqov site, including evidence for different mode of procurement of basalt for the production of handaxes and cleavers, is presented by Golan, Ben Dor & Goren-Inbar (2026). Evidence of selective procurement of flint by Middle Pleistocene hominins from the Gesher Benot Ya'aqov site, as well as evidence of stability of their procurement preferences throughout 50,000 years, is presented by Ekshtain et al. (2026). A study on animals remains from the Caijiagou-C site in the Nihewan Basin (China), providing evidence of systematic processing of ungulate carcasses by early Middle Pleistocene hominins that involved diverse butchery stages, is published by Du et al. (2026). Evidence supporting the reliability of dating of hominin traces from the Quesang site (China) described by Zhang et al. (2021) to the Middle Pleistocene is presented by Gao et al. (2026). A study on Acheulean tools from the Revilleja de Valparaíso (Spain), interpreted as indicative of presence of diverse technological traditions with distinct origins in Western Europe around 700,000 years ago, is published by García-Vadillo et al. (2026). Approximately 430,000-years-old wooden tools are identified from the Marathousa site in the Megalopolis Basin (Greece) by Milks et al. (2026). The conclusions about age of the Petralona skull from the study of Falguères et al. (2025) are contested by Kostopoulos & Lazaridis (2026) and reaffirmed by Falguères et al. (2026).
A less centralized federal system was proposed by Gorbachev during the Communist Party Congress of July 1990. A draft of the New Union Treaty was submitted to the Supreme Soviet of the Soviet Union on 23 November 1990. A drafting committee started work on the text on 1 January 1991. Six of the fifteen Soviet republics, however, did not participate in the drafting of the treaty: Armenia, Georgia, Moldova, Estonia, Latvia and Lithuania. The proposal was approved by the Soviet of the Union on 6 March and sent to the Supreme Soviets of each republic for approval. Agreement could not be reached on the distribution of power between the Union and the Republics and the proposal was not approved. Gorbachev tried to gain popular support for the proposal. On 17 March 1991, the nine republics (Russia, Byelorussia, Ukraine, Azerbaijan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan) which participated in the drafting of the treaty held a popular referendum. 76% of voters supported maintaining the federal system of the Soviet Union, including a majority in all of the nine republics. Opposition was greatest in large cities like Leningrad and Moscow. As the other six republics were already moving towards independence, citizens mostly boycotted the referendum. An agreement between the Soviet central government and the nine republics, known as the 9 + 1 agreement, was finally signed in Novo-Ogaryovo on 23 April. The New Union Treaty would have converted the Soviet Union into a confederation of independent republics with a common president, foreign policy, and military.
Acute myocardial infarction (heart attack) Heart failure (left ventricular systolic dysfunction) Kidney complications of diabetes mellitus (diabetic nephropathy) by means of decreasing the blood pressure and preventing glomerular hyperfiltration injury In treating high blood pressure, ACE inhibitors are a first-line initial drug choice. Age, frailty, and race can influence treatment choices and it is common to need more than one drug to obtain the desired improvement. All ACE inhibitors but enalapril, which can be given intravenously, are administered orally. Each one has different strengths with different starting dosages. Dosage should be adjusted according to the clinical response. Most ACE inhibitors can be dosed once daily with the exception of captopril. ACE inhibitors possess many common characteristics with another class of cardiovascular drugs, angiotensin II receptor antagonists, which are often used when patients are intolerant of the adverse effects produced by ACE inhibitors. ACE inhibitors do not completely prevent the formation of angiotensin II, as blockage is dose-dependent, so angiotensin II receptor antagonists may be useful because they act to prevent the action of angiotensin II at the AT1 receptor, leaving AT2 receptor unblocked; the latter may have consequences needing further study. There are fixed-dose combination drugs, such as ACE inhibitor and thiazide combinations. ACE inhibitors have also been used in chronic kidney failure and kidney involvement in systemic sclerosis (hardening of tissues, as scleroderma renal crisis).
Like PAH metabolites, acrolein is also an electrophilic alkylating agent and permanently binds to the DNA base guanine, by a conjugate addition followed by cyclization into a hemiaminal. The acrolein-guanine adduct induces mutations during DNA copying and thus causes cancers in a manner similar to PAHs. However, acrolein is 1000 times more abundant than PAHs in cigarette smoke and can react without metabolic activation. Acrolein has been shown to be a mutagen and carcinogen in human cells. The carcinogenicity of acrolein has been difficult to study by animal experimentation, because it has such a toxicity that it tends to kill the animals before they develop cancer. Generally, compounds able to react by conjugate addition as electrophiles (so-called Michael acceptors after the Michael reaction) are toxic and carcinogenic, because they can permanently alkylate DNA, similarly to mustard gas or aflatoxin. Acrolein is only one of them present in cigarette smoke; for example, crotonaldehyde has been found in cigarette smoke. Michael acceptors also contribute to the chronic inflammation present in diseases brought about by smoking. Nitrosamines are a group of carcinogenic compounds found in cigarette smoke but not in uncured tobacco leaves. Nitrosamines form on flue-cured tobacco leaves during the curing process through a chemical reaction between nicotine and other compounds contained in the uncured leaf and various oxides of nitrogen found in all combustion gases. Switching to indirect fire curing has been shown to reduce nitrosamine levels to less than 0.1 parts per million.
Under these conditions, if the pathogenic mutation arises after a compensatory mutation, then P can become fixed in the population. The second model of CPDs states that P and C are both deleterious mutations resulting in fitness valleys when mutations occur simultaneously. Using publicly available, Ferrer-Costa et al. 2007 obtained compensatory mutations and human pathogenic mutation datasets that were characterized to determine what causes CPDs. Results indicate that the structural constraints and the location in protein structure determine whether compensated mutations will occur.
Sources: en.wikipedia.org
ICP-MS is more suitable for this application than the previously used thermal ionization mass spectrometry, as species with high ionization energy such as osmium and tungsten can be easily ionized. For high precision ratio work, multiple collector instruments are normally used to reduce the effect noise on the calculated ratios. In the field of flow cytometry, a new technique uses ICP-MS to replace the traditional fluorochromes. Briefly, instead of labelling antibodies (or other biological probes) with fluorochromes, each antibody is labelled with a distinct combinations of lanthanides. When the sample of interest is analysed by ICP-MS in a specialised flow cytometer, each antibody can be identified and quantitated by virtue of a distinct ICP "footprint". In theory, hundreds of different biological probes can thus be analysed in an individual cell, at a rate of ca. 1,000 cells per second. Because elements are easily distinguished in ICP-MS, the problem of compensation in multiplex flow cytometry is effectively eliminated. Laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) is a powerful technique for the elemental analysis of a wide variety of materials encountered in forensic casework. (LA-ICP-MS) has already successfully been applied to applications in forensics, metals, glasses, soils, car paints, bones and teeth, printing inks, trace elemental, fingerprint, and paper. Among these, forensic glass analysis stands out as an application for which this technique has great utility to provide highly.
==== Monitoring ==== The therapeutic target range TSH level for patients on treatment ranges between 0.3 and 3.0 μIU/mL. For hypothyroid patients on thyroxine, measurement of TSH alone is generally considered sufficient. An increase in TSH above the normal range indicates under-replacement or poor compliance with therapy. A significant reduction in TSH suggests over-treatment. In both cases, a change in dose may be required. A low or low-normal TSH value may also signal pituitary disease in the absence of replacement. For hyperthyroid patients, both TSH and T4 are usually monitored. In pregnancy, TSH measurements do not seem to be a good marker for the well-known association of maternal thyroid hormone availability with offspring neurocognitive development. TSH distribution progressively shifts toward higher concentrations with age.
Some journalists and researchers have used the term narcoculture to describe this blend of subcultural references, while others have criticized the label as sensationalistic, noting that cartel recruitment also relies heavily on coercion, patronage networks, and legal businesses. The concept nonetheless points to how cultural symbols and narratives can help cartels normalize their presence and project power.
== Degradation == Modulation of the effects of ANP is achieved through gradual degradation of the peptide by the enzyme neutral endopeptidase (NEP). Recently, NEP inhibitors have been developed, such as Sacubitril and Sacubitril/valsartan. They may be clinically useful in treating patients in heart failure with reduced ejection fraction .
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.